Table 2 Characteristics of the patients at baseline (n = 31) and study characteristics.

n (%)

Sex: women

17 (55)

Responsibility for pharmacotherapy

   Patient only

2 (6)

   Patient supported by caregiver

6 (19)

   Caregiver only

22 (71)

   Professional care only

1 (3)

Antidementia drugs in MEMS^a

   Donepezil

12 (39)

   Galantamine

12 (39)

   Memantine

7 (23)

   Rivastigmine

1 (3)

Regimen of antidementia drug in MEMS^a

   Once daily

24 (75)

   Twice daily

8 (25)

median (range)

Age in years

76 (47-96)

Duration of MEMS monitoring in days^b

180 (140-180)

Duration of antidementia pharmacotherapy at inclusion in months

18 (0-78)

Number of regularly administered drugs

6 (2-12)